Ganaxolone: A Review in Epileptic Seizures Associated with Cyclin‑Dependent Kinase‑Like 5 Deficiency Disorder by Sheridan M. Hoy (4897468)

“…While somnolence and sedation are related to the dose of ganaxolone, they appear early in treatment and may decrease with continued therapy. Thus, although current evidence is somewhat limited, adjunctive ganaxolone could be a valuable therapeutic option for patients aged 2–17 years with epileptic seizures associated with CDD.…”

A schematic depicting the risk of infection from deposited virus-laden droplets and aerosols on porous fomites. by Eloise Parry-Nweye (7548998)

Computational models of catalytic binding sites of two PFK1 iso-enzymes as a docking target for small-molecule cmpd. by Samo Lešnik (21073880)

Sequence analysis of continually RDV selected SARS-CoV-2_Engl2. by Agnieszka M. Szemiel (10196243)

“…Calculated from 988 mutations observed in minimum of 5 sequences. Position of mutation associated with decrease RDV sensitivity in SARS-CoV-2 is highlighted in red and sites identified in murine hepatitis virus (MHV) and Ebola virus (EBOV) are indicated in black. …”

Impaired development of the brain and iBAT of rarely alive adult <i>aP2-Drp1</i>^f/f mice. by Yuta Ibayashi (20404811)

SARS-CoV-2 spike mutation arising <i>in vitro</i> are prevalence in the circulating sequences. by Agnieszka M. Szemiel (10196243)

A meta-regression analysis of undernutrition by year of publication. by Nagwa Farag Elmighrabi (15194969)

Characteristics of treatment modality. by Adekunle Emmanuel Sajo (15285520)

“…The median time to completion of radiotherapy treatment was higher among those who received primary radiotherapy as compared to those who received adjuvant treatment, 51.5 vs 46 days, p 0.039. The annual average age decreased from 56 years to as low as 40 years, a mean difference of 16 years, p 0.012.…”

Demographic and clinical characteristics. by Adekunle Emmanuel Sajo (15285520)

“…The median time to completion of radiotherapy treatment was higher among those who received primary radiotherapy as compared to those who received adjuvant treatment, 51.5 vs 46 days, p 0.039. The annual average age decreased from 56 years to as low as 40 years, a mean difference of 16 years, p 0.012.…”

AUC of various models to predict imeglimin efficacy for liver function evaluated by ROC curves. by Naruyoshi Gyoutoku (22537831)

Subjects:

Apoptotic gene expression induced by propofol. by Yali Ge (417371)

Subjects:

The details of terminal deoxynulceotidyl transferase nick-end-labeling (TUNEL) staining. by Yali Ge (417371)

Subjects:

Result of terminal deoxynulceotidyl transferase nick-end-labeling (TUNEL) staining. by Yali Ge (417371)

Subjects:

Result of whole-mount <i>in situ</i> hybridization at 48 hpf. by Yali Ge (417371)

Subjects:

Apoptotic gene expression without significant changes induced by propofol. by Yali Ge (417371)

Subjects:

Logistic regression analysis to predict the efficacy for liver function. by Naruyoshi Gyoutoku (22537831)

Subjects:

Developmental toxicity induced by 2 μg/ml propofol. by Yali Ge (417371)

Subjects:

Effects of anesthesia on zebrafish locomotion (n = 28). by Yali Ge (417371)

Subjects:

Comparison in baseline variables between efficacy group and non-efficacy group. by Naruyoshi Gyoutoku (22537831)

Subjects:

Comparison of ALT (A), AST (B), and Fib-4 index (C) before and after imeglimin treatment in ALT ≥ 25 IU/L and ALT < 25IU/L groups. by Naruyoshi Gyoutoku (22537831)

Subjects: